Array Biopharma Inc (ARRY) Given a $14.00 Price Target at Piper Jaffray Companies
The firm presently has a "buy" rating on the biopharmaceutical company's stock. Piper Jaffray Companies' price target suggests a potential upside of 80.88% from the stock's previous close.
from Biotech News
0 Comments